CUTERA INC: directors' dealings · United States · SEC (Form 4)

About CUTERA INC

Cutera Inc. (ticker: CUTR) is a United States-based company listed on the NASDAQ market in the United States. Headquartered in Brisbane, California, near San Francisco, Cutera was founded in 1998 and has built a focused franchise in aesthetic and dermatology solutions. For French, Belgian, and Swiss investors, the company represents a specialized medtech name tied to elective procedures, outpatient treatment volumes, and the continued adoption of non-invasive aesthetic technologies. Cutera’s core business is the design, development, manufacture, and commercialization of energy-based systems used by physicians and other qualified practitioners. Its portfolio includes laser, light, and related aesthetic platforms marketed under brands such as excel V, excel HR, xeo, enlighten, truSculpt, and Genesis Plus. These systems address a broad set of indications, including vascular and pigmented lesions, hair removal, skin rejuvenation, and body contouring. In commercial terms, Cutera combines equipment sales with upgrade paths, accessories, and service relationships, which helps support recurring customer engagement and platform expansion over time. The company competes in a crowded global market that includes larger medical device groups and a number of specialized aesthetic technology vendors. Its competitive positioning is based less on scale than on product breadth, technical specialization, and international reach. According to company materials, Cutera distributes globally through channels in more than 65 countries and maintains international offices in Australia, Belgium, Canada, France, Hong Kong, Japan, and Switzerland. That footprint gives the business a geographically diversified revenue base and places it close to key medical aesthetics markets. Recent corporate developments have centered on financial restructuring. In March 2025, Cutera announced a restructuring transaction supported by existing lenders that was intended to reduce debt by nearly $400 million and provide $65 million of new money. In May 2025, the company said it had successfully completed the process and emerged from Chapter 11 with an improved capital structure. For investors, this is a major event because it signals both prior balance-sheet stress and a reset that may support business continuity and operational focus going forward. Overall, Cutera remains a niche but recognizable player in the aesthetics segment of Health & Pharma. Its investment profile is shaped by the long-term demand for non-invasive cosmetic treatments, its international distribution network, and the aftereffects of its recent restructuring, which remain central to assessing execution and financial risk.